Associated Papers
Mapping multimodal phenotypes to perturbations in cells and tissue with CRISPRmap.
Gu J et al.
Nature Biotechnology, 2025
39375448 (PubMed )
Supplement: 41587_2024_2386_MOESM1_ESM.pdf
Functional evaluation and clinical classification of BRCA2 variants.
Huang H et al.
Nature, 2025
39779857 (PubMed )
Supplement: 41586_2024_8388_MOESM3_ESM.xlsx › Table_S4A
CRISPRmap: Sequencing-free optical pooled screens mapping multi-omic phenotypes in cells and tissue.
Gu J et al.
Biorxiv : the Preprint Server for Biology, 2023
38234835 (PubMed )
Supplement: media-5.xlsx › ClinVar_update_Dec2023
BRCA2 reversion mutation confers resistance to olaparib in breast cancer.
Yamamoto S et al.
Clinical Case Reports, 2023
Landscape of potentially targetable receptor tyrosine kinase fusions in diverse cancers by DNA-based profiling.
Wang T et al.
Npj Precision Oncology, 2022
36369474 (PubMed )
Supplement: 41698_2022_325_MOESM1_ESM.pdf
GEMO, a National Resource to Study Genetic Modifiers of Breast and Ovarian Cancer Risk in BRCA1 and BRCA2 Pathogenic Variant Carriers.
Lesueur F et al.
Frontiers in Oncology, 2018
30430080 (PubMed )
Supplement: Table_2.XLSX › Supplementary_Table_2
New recurrent BRCA1/2 mutations in Polish patients with familial breast/ovarian cancer detected by next generation sequencing.
Kluska A et al.
Bmc Medical Genomics, 2015
Evaluation of the role of Finnish ataxia-telangiectasia mutations in hereditary predisposition to breast cancer.
Pylkäs K et al.
Carcinogenesis, 2007
Select a paper to view details